RenovoRx (RNXT) Q3 2026 Earnings Call Transcript
RenovoRx (RNXT) reported Q3 2026 earnings, highlighting growth in active commercial cancer centers (26 up from 21) and a robust commercial funnel. The company expects to meet its year-end target of 36 active centers. Revenue guidance remains $3.75M-$4.25M. New account activations and repeat orders are key growth metrics. RenovoCath's use expanded to sarcoma and a neoadjuvant trial, with 10 issued U.S. patents and more pending.
How this was made

The 30-second read
Why it matters
The key tradable items are operating KPIs (active commercial centers, commercial funnel size, repeat ordering) and the reaffirmed full-year 2026 revenue guidance range, which together inform expectations for near-term execution.
Market read
Investors can update positioning based on management’s stated activation pace, funnel expansion, and reaffirmed revenue guidance for 2026.
What to watch
The transcript emphasizes activations and repeat orders but provides limited detail on unit economics, reimbursement dynamics, or competitive landscape that could affect sustainability of growth.
Background
The article is a transcript of RenovoRx’s Q3 2026 earnings call, focused on commercialization of RenovoCath/TAMP for pancreatic cancer and expansion into other solid tumors.
Ticker impact
RenovoRx reports Q3 2026 call metrics, including active commercial cancer center customers rising 21 to 26 and maintaining 2026 revenue guidance of $3.75M to $4.25M.
Likely upward bias as investors price in continued commercial activation momentum and guidance reaffirmation.
The transcript provides specific operating KPIs and a reiterated revenue range, which can drive sentiment and positioning ahead of subsequent updates.
Market effects
Reinforces investor interest in localized drug delivery platforms for interventional oncology, potentially improving sentiment toward similar device-enabled oncology approaches.
No clear regional read-through beyond U.S. cancer-center commercialization.
Limited direct global impact; discussion is primarily U.S. commercial adoption and U.S. patent activity.
Counterpoint
Commercial progress may still be early relative to the addressable market, and guidance is a narrow range that could be sensitive to activation pace.
Key entities
- companyRenovoRx
Subject of the earnings call transcript; reports active commercial center growth, commercial funnel expansion, IP updates, and reiterates 2026 revenue guidance.
- productRenovoCath
Device enabling TAMP localized drug delivery; discussed as driving account activations and repeat orders.
- clinical_programTIGeR-PaC trial
Phase III trial for locally advanced pancreatic cancer evaluating targeted delivery of gemcitabine versus systemic gemcitabine plus Abraxane.

